Role of the Wilms' tumor 1 gene in the aberrant biological behavior of leukemic cells and the related mechanisms

Oncology Reports

Volumn 32, Issue 6, 2014, Pages 2680-2686

  Li, Yan ^a   Wang, Jiying ^a   Li, Xiaoyan ^a   Jia, Yujiao ^a   Huai, Lei ^a   He, Kan ^a   Yu, Pei ^a   Wang, Min ^a   Xing, Haiyan ^a   Rao, Qing ^a   Tian, Zhen ^a   Tang, Kejing ^a   Wang, Jianxiang ^a   Mi, Yingchang ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Cell cycle; Leukemia; Proliferation; RNAi technology; Wilms' tumor 1 gene

Indexed keywords

BETA CATENIN; CELL PROTEIN; CYCLIN D1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN SUZ12; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; WNT11 PROTEIN; WNT3A PROTEIN; WNT5A PROTEIN; WT1 PROTEIN; CURCUMIN; WT1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CLONOGENESIS; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DNA DETERMINATION; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; LEUKEMOGENESIS; M PHASE CELL CYCLE CHECKPOINT; MOLECULAR CLONING; ONCOGENE; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WT1 GENE; BIOSYNTHESIS; CELL CYCLE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; K562 CELL LINE; NEPHROBLASTOMA; PATHOLOGY; U937 CELL LINE; WNT SIGNALING PATHWAY;

APOPTOSIS; BETA CATENIN; CELL CYCLE; CELL PROLIFERATION; CURCUMIN; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; U937 CELLS; WILMS TUMOR; WNT SIGNALING PATHWAY; WT1 PROTEINS;

EID: 84914669265     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3529     Document Type: Article

References (20)

1. Yang L, Han Y, Suarez Saiz F and Minden MD: A tumor suppressor and oncogene: the WT1 story. Leukemia 21: 868-876, 2007
2. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Chanarat P and Limtrakul P: Curcumin inhibits WT1 gene expression in human leukemic K562 cells. Acta Pharmacol Sin 27 360-366, 2006.
3. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP and Rauscher FJ III: Repression of the insulinlike growth factor II gene by the Wilms tumor suppressor WT1. Science 257 674-678, 1992.
4. Wang ZY, Qiu QQ, Huang J, Gurrieri M and Deuel TF: Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways. Oncogene 10: 415-422, 1995
5. Laity JH, Chung J, Dyson HJ and Wright PE: Alternative splicing of Wilms' tumor suppressor protein modulates DNA binding activity through isoform-specific DNA-induced conformational changes. Biochemistry 39: 5341-5348, 2000.
6. Han Y, San-Marina S, Liu J and Minden MD: Transcriptional activation of c-myc proto-oncogene by WT1 protein. Oncogene 23: 6933-6941, 2004
7. Smith SI, Down M, Boyd AW and Li CL: Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice. Cancer Res 60: 808-814, 2000.
8. Haber DA, Park S, Maheswaran S, et al: WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science 262: 2057-2059, 1993.
9. + haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 116: 409-420, 2002.
10. Baird PN and Simmons PJ: Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 25: 312-320, 1997.
11. Zhi L, Zhang J, Jia Y, et al: Effect of G-rich oligonucleotides on the proliferation of leukemia cells and its relationship with p53 expression. Oligonucleotides 21: 21-27, 2011.
12. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
13. Wang Y, Zhang H, Chen Y, et al: LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138: 660-672, 2009.
14. Svensson E, Vidovic K, Lassen C, et al: Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells. Leukemia 21: 2485-2494, 2007.
15. Radich JP, Dai H, Mao M, et al: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103: 2794-2799, 2006.
16. Varma N, Anand MS, Varma S and Juneja SS: Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia. Leuk Lymphoma 52: 687-693, 2011.
17. Østergaard M, Nyvold CG, Jovanovic JV, et al: Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. Leukemia 25: 1168-1173, 2011.
18. Kim MK, McGarry TJ, O'Broin P, Flatow JM, Golden AA and Licht JD: An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. Proc Natl Acad Sci U SA 106: 11154-11159, 2009.
19. Siapati EK, Papadaki M, Kozaou Z, et al: Proliferation and bone marrow engraftment of AML blasts is dependent on β-catenin signalling. Br J Haematol 152: 164-174, 2011.
20. Nakagawa M, Tsuzuki S, Honma K, Taguchi O and Seto M: Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells. Haematologica 96: 1318-1326, 2011.